Marker Therapeutics Inc (MRKR)

[Sugarshaker]

Burrhead I think they are not giving the shareholders the truth about the trials and where the MSKCC trial is currently.

Second qtr earnings,

Results from the planned interim analysis are expected to be available later in 2017. If the safety profile remains favorable and there are sufficient signs of tumor response, patient enrollment will resume and TapImmune expects the study to be completed as planned in 2018.

Third qtr earnings,

Data from the first 27 patients enrolled in the study are currently being analyzed by the study's clinical investigators at MSKCC. TapImmune anticipates reporting the results based on these 27 patients in the first half of 2018. If the safety profile remains favorable and there are sufficient signs of tumor response, patient enrollment may resume and the study can be completed as designed.

Year end 2016 update,

Sponsored by Memorial Sloan Kettering Cancer Center (MSKCC), this 40-patient, single-arm study will enroll women who either progressed while receiving or within six months of completing platinum-based therapy. TPIV 200 will be tested in combination with another immunotherapy: AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab. Successfully completing the first safety cohort enabled MSKCC to increase the number of patients that can be enrolled and will subsequently increase the study's enrollment rate. Currently more than 50% of patients have been enrolled. An interim analysis is planned in the fourth quarter of 2017.